Regulus Therapeutics Inc

NASDAQ:RGLS   4:00:00 PM EDT
1.56
+0.04 (+2.63%)
7:59:12 PM EDT: $1.77 +0.21 (+13.46%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Regulus Therapeutics Inc Stock, NASDAQ:RGLS

4224 Campus Point Court, Suite 210, San Diego, California 92121
United States of America
Phone: +1.858.202.6300
Number of Employees: 26

Description

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.